InterCure Ltd.

INCR Healthcare Drug Manufacturers Specialty & Generic

InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.

3.25 0.05 −1.52%
Market cap
$39.1M
P/E
6.2×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
−0.13
Beneish M
−2.77
Dividend safety
n/a

InterCure Ltd. (INCR) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, InterCure Ltd. (INCR) trades at a P/E ratio of 6.2×. Over the past ten years it has ranged from 1.1× (March 2023) to 290× (April 2021); the current reading is higher than 74% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 1.7× (42.77%)
FY2024 3.0× 22.31%
FY2023 2.5× 10.65%
FY2022 2.2× (94.61%)
FY2021 41.2× (19.10%)
FY2020 50.9× 0.00%
FY2019 50.9× —

Quarterly newest first

Period P/E ratio Change
Jun 2023 16.1× 686.91%
Mar 2023 2.0× (8.05%)
Dec 2022 2.2× (34.55%)
Sep 2022 3.4× (39.84%)
9 more quarters

Against its own ten years

Low 1.1× High 290×
Ten-year median 3.2×
Current reading's percentile 74

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on INCR